Caribou Biosciences to Discontinue CAR-T Programs and Explore Strategic Alternatives
Caribou Biosciences (NASDAQ: CRBU) has announced the discontinuation of its allogeneic CAR-T programs, vispa-cel and CB-011. The company will now focus on exploring strategic alternatives such as mergers, acquisitions, or business combinations involving either the entire firm or specific assets. Vispa-cel was being developed to treat relapsed/refractory B-cell malignancies but has not yet reached regulatory approval. This decision reflects a shift in strategy amid ongoing challenges and limited progress with these programs. The move is expected to impact investor sentiment, particularly for those who had high hopes for the CAR-T therapies. The company's pivot signals uncertainty about its current pipeline and may lead to significant changes in ownership or direction.
Tickers: $CRBU